Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Age-related macular degeneration (AMD) is a leading cause of blindness. Genetic variants at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFHR1-5) are major determinants of AMD susceptibility, but their molecular consequences remain unclear. Here we demonstrate that FHR-4 plays a prominent role in AMD pathogenesis. We show that systemic FHR-4 levels are elevated in AMD (P-value = 7.1 × 10), whereas no difference is seen for FH. Furthermore, FHR-4 accumulates in the choriocapillaris, Bruch's membrane and drusen, and can compete with FH/FHL-1 for C3b binding, preventing FI-mediated C3b cleavage. Critically, the protective allele of the strongest AMD-associated CFH locus variant rs10922109 has the highest association with reduced FHR-4 levels (P-value = 2.2 × 10), independently of the AMD-protective CFHR1-3 deletion, and even in those individuals that carry the high-risk allele of rs1061170 (Y402H). Our findings identify FHR-4 as a key molecular player contributing to complement dysregulation in AMD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005798 | PMC |
| http://dx.doi.org/10.1038/s41467-020-14499-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.
Deep Learning-Based Detection of Reticular Pseudodrusen in Age-Related Macular Degeneration.
Clin Exp Ophthalmol
September 2025
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
Background: Reticular pseudodrusen (RPD) signify a critical phenotype driving vision loss in age-related macular degeneration (AMD). This study sought to develop and externally test a deep learning (DL) model to detect RPD on optical coherence tomography (OCT) scans with expert-level performance.
Methods: RPD were manually segmented in 9800 OCT B-scans from individuals enrolled in a multicentre randomised trial.
Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration.
Acta Ophthalmol
September 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Purpose: To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration (nAMD).
Methods: This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti-VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.
[Cellular models of inflammation in the posterior segment of the eye: exploring pathogenic mechanisms].
Med Sci (Paris)
September 2025
Département d'ophtalmologie et d'oto-rhino-laryngologie - chirurgie cervico-faciale, Faculté de médecine, Université Laval, Québec, Canada - CUO-Recherche, Médecine régénératrice, Centre de recherche du CHU de Québec - Université Laval, Québec, Canada.
Glaucoma, age-related macular degeneration, and diabetic retinopathy are complex eye diseases that involve inflammation. Several cellular models are developed to study inflammation mechanisms in the posterior segment of the eye. These models, are composed of cells of various origins (human or animal), derived from different tissues (retina, choroid, skin, and umbilical cord) and belonging to different cell types (epithelial, endothelial, vascular, and neuronal).
View Article and Find Full Text PDFRecurrence associated with 2-year visual acuity after subretinal tissue plasminogen activator for submacular hemorrhage in neovascular age-related macular degeneration.
Jpn J Ophthalmol
September 2025
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto City, Kyoto Prefecture, 606-8507, Japan.
Purpose: To identify predictors of the 2-year best-corrected visual acuity (BCVA) after subretinal tissue plasminogen activator (tPA) injection for massive submacular hemorrhage (SMH) complicating neovascular age-related macular degeneration (nAMD).
Study Design: A prospective, observational study.
Methods: This study included consecutive eyes with massive SMH and nAMD that underwent vitrectomy with subretinal tPA injection and follow-up for 2 years.